RXRX
NASDAQRecursion Pharmaceuticals Inc.
Price$3.46-0.44 (-11.40%)
01:30 PM07:45 PM
News · 26 weeks67+225%
2026-04-192026-10-11
Mix2890d
- Insider11(39%)
- Other9(32%)
- SEC Filings7(25%)
- Earnings1(4%)
Latest news
25 items- SECSEC Form 424B5 filed by Recursion Pharmaceuticals Inc.424B5 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Filer)
- SECSEC Form 8-K filed by Recursion Pharmaceuticals Inc.8-K - RECURSION PHARMACEUTICALS, INC. (0001601830) (Filer)
- PRRecursion Announces Sanofi Options Potential First-in-Class Immunology Development Candidate from Their CollaborationSalt Lake City, UT, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. ("Recursion") (NASDAQ:RXRX), a leading clinical-stage company pioneering AI-enabled drug discovery and development decoding biology to radically improve lives, today announced that Sanofi has optioned the first development candidate from the two companies’ multi-program research collaboration. The option triggered a $10 million milestone payment to Recursion, bringing total upfront and milestone payments received from Sanofi under the collaboration to $144 million; Recursion is eligible for more than $300 million in additional milestones under the program, with double digit royalties on net product sa
- PRRecursion Announces Pricing of $200 Million Underwritten Offering of Class A Common StockSalt Lake City, UT, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. ("Recursion") (NASDAQ:RXRX), a leading clinical-stage company pioneering AI-enabled drug discovery and development decoding biology to radically improve lives, today announced the pricing of an underwritten offering of 61,540,000 shares of its Class A common stock at a price of $3.25 per share. All of the shares are to be sold by Recursion. Before deducting the underwriting discounts and commissions and estimated offering expenses, Recursion expects to receive total gross proceeds of approximately $200 million. The offering is expected to close on or about October 16, 2026, subject to satisfaction of cust
- SECSEC Form 424B5 filed by Recursion Pharmaceuticals Inc.424B5 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Filer)
- PRRecursion Announces $200 Million Oversubscribed Follow-On Offering, Clinical Data Updates, and Partnership MilestoneLeading Healthcare Investors, including Janus Henderson Investors, Invus, Longaeva Partners, ARK Invest, Driehaus Capital Management and other prominent healthcare specialists and mutual funds invest $200 million in RecursionREC-4881 (MEK1/2 inhibitor) Phase 1b/2 Data Update: Deep, durable polyp burden reductions reproduced in the expanded adult FAP population (18+), with a 47% median reduction after 12 weeks of treatment and 85% of patients maintaining reductions below baseline after 12 weeks off treatment. New upper GI data, addressing the area of greatest unmet medical need in FAP, show a 55% median polyp burden reduction, including two patients with ≥98% polyp burden reduction, and 92% o
- INSIDERSEC Form 4 filed by Recursion Pharmaceuticals Inc.4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
- INSIDERSEC Form 4 filed by Recursion Pharmaceuticals Inc.4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
- SECSEC Form 144 filed by Recursion Pharmaceuticals Inc.144 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Subject)
- INSIDERDirector Dar Zavain was granted 4,607 shares, increasing direct ownership by 2% to 245,371 units (SEC Form 4)4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
- INSIDERDirector Li Dean Y was granted 3,378 shares, increasing direct ownership by 0.23% to 1,476,707 units (SEC Form 4)4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
- PRTempus and Recursion Extend Existing Data License Agreement and Enter New License Agreement for Recursion’s RNA Foundation ModelTempus AI, Inc. (NASDAQ:TEM) today announced an extension of its data license agreement with Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX). Additionally, the two companies have entered into a new agreement under which Tempus will license Recursion’s RNA Foundation Model. Tempus and Recursion have extended their multi-year data partnership through November 2029. The companies share a mission to use foundation models to advance precision medicine, and entered into a collaboration that was first established in 2023. In connection with the extension of the collaboration’s committed term, the parties agreed to amend the Annual License Fees payable under the original Master Agreement, replacing
- SECRecursion Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement8-K - RECURSION PHARMACEUTICALS, INC. (0001601830) (Filer)
- INSIDERChief Financial Officer Taylor Ben R covered exercise/tax liability with 5,396 shares, decreasing direct ownership by 0.50% to 1,071,462 units (SEC Form 4) (withholding obligation)4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
- INSIDERCEO and President Khan Najat sold $78,822 worth of shares (22,408 units at $3.52) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 2,072,890 units (SEC Form 4)4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
- PRThe Market Just Told You Which Layer Of AI Biology It Is Paying ForAUSTIN, Texas, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Market Updates News Commentary - Earnings season in life sciences technology has just delivered an unusually clean verdict. The company that owns the industry’s data and systems of record beat and jumped. The company selling model-informed software into the same customers missed and fell by roughly the same amount on the day. The AI-native discovery company reported a fraction of the revenue analysts expected. Read together, those three results say something specific about where value is accruing in AI-enabled drug discovery, and it is not where most of the narrative has been pointed. Companies mentioned in today’s commentary include: Mind
- INSIDERDirector Borgeson Blake sold $100,200 worth of shares (30,000 units at $3.34) as part of a pre-agreed trading plan, decreasing direct ownership by 0.48% to 6,158,287 units (SEC Form 4)4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
- INSIDERCEO and President Khan Najat covered exercise/tax liability with 80,498 shares, decreasing direct ownership by 4% to 2,095,298 units (SEC Form 4) (withholding tax)4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
- INSIDERChief Financial Officer Taylor Ben R covered exercise/tax liability with 25,018 shares, decreasing direct ownership by 2% to 1,076,858 units (SEC Form 4) (for withholding tax)4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
- INSIDERChief Scientific Officer Hallett David covered exercise/tax liability with 26,657 shares, decreasing direct ownership by 2% to 1,043,837 units (SEC Form 4) to cover taxes4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
- SECSEC Form SCHEDULE 13G filed by Recursion Pharmaceuticals Inc.SCHEDULE 13G - RECURSION PHARMACEUTICALS, INC. (0001601830) (Subject)
- INSIDERDirector Borgeson Blake sold $97,500 worth of shares (30,000 units at $3.25) as part of a pre-agreed trading plan, decreasing direct ownership by 0.48% to 6,188,287 units (SEC Form 4)4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
- SECSEC Form 10-Q filed by Recursion Pharmaceuticals Inc.10-Q - RECURSION PHARMACEUTICALS, INC. (0001601830) (Filer)
- SECRecursion Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - RECURSION PHARMACEUTICALS, INC. (0001601830) (Filer)
- PRRecursion Reports Second Quarter Financial Results; Genentech Options First Neuroscience Target into Early Discovery ProgramGenentech advanced the collaboration's first neuroscience target into a joint early discovery program, providing early evidence that Recursion's platform can generate novel, biologically validated targets for drug discoveryREC-4881 (MEK1/2 inhibitor): Additional Phase 2 data in Familial Adenomatous Polyposis (FAP) to be presented at the Presidential Plenary session at leading hereditary GI annual meeting in November 2026REC-7735 (PI3Kα H1047R inhibitor): IND cleared, Phase 1/2 trial start in 2H26; a >100× mutant-selective PI3Kα H1047R inhibitor designed to improve therapeutic index by enabling deep suppression of the most common activating PI3Kα mutation while sparing wild-type PI3Kα Reduced
RXRX FAQ
7 questionsWhat does Recursion Pharmaceuticals Inc. do?
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. It has four clinical-stage drug candidates focused on rare, monogenic diseases; and 33 additional programs in various stages of preclinical development. Recursion Pharmaceuticals, Inc. has strategic agreements with Bayer; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. The company was founded in 2013 and is...Where does RXRX stock trade?
Recursion Pharmaceuticals Inc. (RXRX) is listed on NASDAQ.What sector and industry is RXRX in?
Recursion Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Recursion Pharmaceuticals Inc. go public?
Recursion Pharmaceuticals Inc. (RXRX) completed its IPO in 2021.What are analysts saying about RXRX?
Recursion Pharmaceuticals Inc. has had 8 recent analyst actions on file. The most recent action was from Analyst: Overweight with a $1100.00 price target on 2025-12-17.What companies are similar to RXRX?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare RXRX side-by-side with any of them on Quantisnow.How can I track RXRX on Quantisnow?
Quantisnow aggregates Recursion Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow RXRX to receive live email and push alerts on every new disclosure.